Regenovo
Develops medical-grade 3D bioprinters and bioinks for creating living tissue scaffolds, enabling applications in drug screening, regenerative medicine, and personalized medical devices
- CEO / Founder
- Xu Mingen
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- >$15M (partial; later rounds undisclosed)
- Latest Round
- Venture Round
- Key Investors
- Xu Mingen (~28% largest shareholder); Shining3D / 先临三维 (~17%, no longer controlling); Proya / 珀莱雅; Zheshang Venture Capital / 浙商创投; Puhua Capital / 普华资本; Qinbing Investment / 秦兵投资; Hewan Investment / 和湾投资; Qiantang Industry Group / 钱塘产业集团; Zhejiang Rongsheng Holdings; Hangzhou Economic Development Zone VC; Peng Rui Group / 鹏瑞集团; other private investors
Technology & Products
Key Products
Regenovo 3D Bioprinters (e.g., Bio-Architect X), bioinks, biomaterials, skin models, micro-liver models.
Technological Advantage
Patented technology for real-time cell microenvironment monitoring (verified); proprietary bioink formulations and precision control systems (claimed); complete digital medical chain from medical information to 3D printed medical products
Differentiation
Value Proposition
Provides complete biological 3D printing solutions from equipment to materials, reducing tissue engineering development time and enabling personalized medical treatments
How They Differentiate
Focus on real-time cell microenvironment monitoring (unique among competitors); complete solution from printers to biomaterials vs competitors' narrower focus; strong academic partnerships in China vs global competitors' different geographic focus
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, hospitals, and medical device manufacturers
Industry Verticals
Pharmaceutical; Medical Research; Healthcare; Biotechnology
Competitors
Organovo, CELLINK, Rokit Healthcare
Growth & Milestones
Growth Metrics
Developed China's first commercial 3D bioprinter in 2013; Over 50 bioprinters installed in research institutions and hospitals across China; Published more than 100 research papers in bioprinting field; Received multiple national and provincial research grants
Major Milestones
Founded in 2013 as joint venture by Xiangli 3D; Developed world's first real-time cell microenvironment monitoring 3D printer; Hosted 5th Regenovo Biological 3D Printing Summit in 2021; Achieved national-level specialized and innovative enterprise status
Notable Customers
Hangzhou University of Science and Technology; Zhejiang University School of Medicine; Shanghai Ninth People's Hospital; Chinese Academy of Sciences
Equipment deals on record
Publicly disclosed purchases or installs only.
- 高精度3D打印机/壹套Buyer: Tongji University · Supplier: 杭州捷诺飞生物科技股份有限公司